AIGH Capital Management’s Aprea Therapeutics APRE Stock Holding History

AIGH Capital Management’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$762K	Hold	1,015,541	–	–	0.08%	43
2026 Q2	$815K	Hold	1,015,541	–	–	0.05%	42
2026 Q1	$775K	Buy	1,015,541 +645,000	+174%	+$507K	0.11%	40
2025 Q4	$316K	Sell	370,541 -168,759	-31%	-$207K	0.08%	34
2025 Q3	$795K	Hold	539,300	–	–	0.22%	37
2025 Q2	$913K	Hold	539,300	–	–	0.41%	28
2025 Q1	$1.1M	Hold	539,300	–	–	0.46%	35
2024 Q4	$1.77M	Hold	539,300	–	–	0.55%	28
2024 Q3	$1.48M	Hold	539,300	–	–	0.42%	30
2024 Q2	$2.19M	Hold	539,300	–	–	0.68%	24
2024 Q1	$3.5M	Buy	539,300 +190,000	+54%	+$1.18M	1.05%	27
2023 Q4	$1.64M	Hold	349,300	–	–	0.65%	32
2023 Q3	$1.46M	Hold	349,300	–	–	0.69%	35
2023 Q2	$1.1M	Buy	349,300 +4,300	+1%	+$16K	0.45%	39
2023 Q1	$1.53M	Buy	+345,000	New	+$2.55M	0.56%	37

Other funds holding APRE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

AIGH Capital Management's APRE Position: Q3 2026 in Review

AIGH Capital Management held its Aprea Therapeutics (APRE) position steady in Q3 2026 at 1,015,541 shares worth $762K. The position accounts for 0.08% of the portfolio, ranked #43.

AIGH Capital Management first reported a position in APRE in Q1 2023 and has held it in 15 quarters since. The position peaked at $3.5M in Q1 2024. 6 funds tracked by Wall St. Rank hold APRE as of Q3 2026.

AIGH Capital Management held 1,015,541 shares of Aprea Therapeutics worth $762K as of Q3 2026.
AIGH Capital Management left its Aprea Therapeutics share count unchanged in Q3 2026.
Aprea Therapeutics made up 0.08% of AIGH Capital Management's portfolio in Q3 2026, its #43 holding.
AIGH Capital Management first reported a position in Aprea Therapeutics in Q1 2023 and has held it in 15 quarters since.
AIGH Capital Management's Aprea Therapeutics position peaked at $3.5M in Q1 2024.
6 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.

Based on AIGH Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.